Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal ...

Retrieved on: 2021-03-30 06:00:00

Tags for this article:

Medical specialties

Clinical medicine

Medicine

Immunology

Monoclonal antibodies

Arthritis

Autoimmune diseases

Cytokine release syndrome

Click the tags to see associated articles and topics

Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal .... View article details on HISWAI: https://www.biospace.com/article/releases/tiziana-plans-phase-2-clinical-study-in-moderate-to-severe-covid-19-patients-with-nasal-administration-of-foralumab-a-fully-human-anti-cd3-monoclonal-antibody/

Excerpt

... administered Foralumab is through the modulation of the immune system and not by directly targeting Covid-19, this therapeutic approach could be ...

Article found on: www.biospace.com

View Original Article